Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.

[1]  H. Ueno,et al.  Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors. , 2005, Bioorganic & Medicinal Chemistry Letters.

[2]  Y. Matsumoto,et al.  Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives. , 2004, Bioorganic & medicinal chemistry.

[3]  H. Ueno,et al.  Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa. , 2004, Bioorganic & medicinal chemistry letters.

[4]  H. Matter,et al.  Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. , 2004, Bioorganic & medicinal chemistry letters.

[5]  Gerhard Klebe,et al.  Understanding protein-ligand interactions: the price of protein flexibility. , 2004, Journal of molecular biology.

[6]  H. Nar,et al.  Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents. , 2003, Bioorganic & medicinal chemistry letters.

[7]  K. Ishikawa,et al.  Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids. , 2003, Journal of medicinal chemistry.

[8]  Gerhard Klebe,et al.  Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity. , 2003, Journal of molecular biology.

[9]  John P. Overington,et al.  Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence. , 2002, Journal of medicinal chemistry.

[10]  H. Kurihara,et al.  The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor. , 2002, Bioorganic & Medicinal Chemistry.

[11]  H. Nar,et al.  Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.

[12]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[13]  P. Lam,et al.  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.

[14]  J. Stürzebecher,et al.  Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. , 1999, Thrombosis research.

[15]  M. Morrissey,et al.  Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor XA inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[16]  Y. Matsumoto,et al.  Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. , 1998, European journal of pharmacology.

[17]  Y. Matsumoto,et al.  Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs. , 1998, European journal of pharmacology.

[18]  Y. Matsumoto,et al.  Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis , 1998, Thrombosis and Haemostasis.

[19]  P. Weber,et al.  Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. , 1998, Bioorganic & medicinal chemistry letters.

[20]  Y. Matsumoto,et al.  Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis , 1998, Thrombosis and Haemostasis.

[21]  Y. Matsumoto,et al.  Antithrombotic effects of YM‐60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time , 1998, British journal of pharmacology.

[22]  Y. Matsumoto,et al.  Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. , 1998, Japanese journal of pharmacology.

[23]  M. J. Fisher,et al.  Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa. , 1997, Journal of medicinal chemistry.

[24]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[25]  B. Judkins,et al.  A versatile synthesis of amidines from nitriles via amidoximes , 1996 .

[26]  Robert Huber,et al.  X-ray Structure of Active Site-inhibited Clotting Factor Xa , 1996, The Journal of Biological Chemistry.

[27]  P. Hadváry,et al.  Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. , 1996, Journal of medicinal chemistry.

[28]  R. Huber,et al.  Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin , 1995, FEBS letters.

[29]  S. Katakura,et al.  Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. , 1994, Journal of medicinal chemistry.

[30]  S. Katakura,et al.  A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. , 1993, Biochemical and biophysical research communications.

[31]  J. Maraganore,et al.  Thrombin-specific inhibition by and slow cleavage of hirulog-1. , 1992, The Biochemical journal.

[32]  J. Hauptmann,et al.  Pharmacology of Synthetic Thrombin Inhibitors of the Tripeptide Type , 1992 .

[33]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[34]  S. Whitebread,et al.  Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives. , 1991, Journal of medicinal chemistry.

[35]  J. Hirsh.  Oral anticoagulant drugs. , 1991, The New England journal of medicine.

[36]  E. Frérot,et al.  PyBOP® and PyBroP: Two reagents for the difficult coupling of the α,α-dialkyl amino acid, Aib. , 1991 .

[37]  T. Tezuka,et al.  Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of N alpha-substituted L-arginine. , 1980, Journal of medicinal chemistry.

[38]  K. Váradi,et al.  Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation. , 1979, Thrombosis research.

[39]  J. E. Oliver,et al.  A Knoevenagel-Type Synthesis of Styrene-ω-sulfonanilides , 1975 .

[40]  A. Pinner,et al.  Umwandlung der Nitrile in Imide , 1878 .